Trans women discuss using finasteride and dutasteride for hair loss and whether to continue after testosterone suppression. One user reduced dutasteride dosage after achieving undetectable testosterone levels.
A user experienced significant hair regrowth using Minoxidil but started shedding hair after switching brands and adding treatments like Topical Finasteride and microneedling. They also faced increased hair loss after using Ketoconazole shampoo and are seeking advice on whether brand switching or the shampoo could be the cause.
Balding scalps have more androgen receptors, leading to increased TGF-beta, which causes blood vessel loss and hair follicle miniaturization. Blocking androgen signaling and TGF-beta may help prevent hair loss.
The conversation discusses switching from RU58841 to pyrilutamide for hair loss treatment, with users generally recommending staying on RU58841 if it is effective. RU58841 is sourced from GeneTherica, which ships worldwide.
The user switched from finasteride to dutasteride and experienced heavy shedding around six months in, affecting even transplanted hair. They are seeking others' experiences with similar shedding after switching to dutasteride.
The user is considering switching from finasteride and minoxidil to dutasteride for better hair regrowth results, as they are experiencing thinning and shedding despite current treatments. They have also tried microneedling, Clobetasol, and salicylic acid to manage scalp issues and inflammation.
Hair regrowth and gender transition using finasteride, estrogen, and spironolactone. Significant hair regrowth and personal transformation were achieved through hormone replacement therapy.
Switching from finasteride to dutasteride caused significant shedding but minimal side effects. The user plans to continue dutasteride for 12 months despite concerns about hair density.
Switching from propylene glycol to glycerin in topical finasteride may reduce systemic absorption and side effects while maintaining local scalp DHT suppression. Concerns exist about glycerin's ability to deliver the full dose to hair follicles.
The conversation discusses switching from finasteride to dutasteride for hair loss treatment, with mixed experiences regarding shedding and effectiveness. Some users also mention using minoxidil and RU58841 alongside these treatments.
The conversation discusses a clinical trial for Setipiprant in the US, starting June 29th, with eligibility excluding recent users of minoxidil or finasteride. It encourages informed decision-making before signing up.
Pyrilutimide and CB-03-01, two treatments for hair loss, have similar clinical trial results despite different binding affinities to androgen receptors. Factors other than binding affinity, like the time a drug stays bound to the receptor, may influence their effectiveness.
27-year-old female experiences aggressive hair thinning and hirsutism despite normal testosterone levels. Spironolactone and 2% minoxidil were ineffective; high DHEA sulfate levels may be the cause.
Concerns about the long-term effects of dutasteride and finasteride on fertility, with discussions on cycling these medications to mitigate risks. The conversation highlights skepticism about study methodologies and the importance of weighing treatment risks against potential fertility issues.
ABS-201 shows promise for male hair regrowth by blocking the prolactin receptor, with higher expected efficacy than current treatments. The discussion also covers dosing differences between macaques and humans for hmi115, highlighting a significant dosage disparity.
The conversation discusses using 1% cetirizine, an antihistamine, as a potential treatment for androgenetic alopecia (hair loss). One user plans to try cetirizine instead of finasteride, while others are curious or skeptical about its effectiveness, discussing the role of inflammation in hair loss.
The user has been using finasteride inconsistently for 2 years and minoxidil for 6 months without seeing hair growth. They are considering switching to dutasteride and restarting minoxidil to address thinning at the right temple, with advice suggesting consistent use for better results.
Clascoterone's European release is expected in Q4 2026, with FDA approval anticipated by mid-2027. The discussion includes questions about the approval timeline and potential acceleration due to unmet needs.
Switching from Accord to Aurobindo finasteride initially reduced hair shedding, but after three months, shedding increased again. Users discuss varying experiences with different finasteride brands, with some suggesting brand differences may not matter.
The user has been using finasteride for 9 months, which initially stopped hair loss, but recently hair loss has resumed. They are considering switching to dutasteride.
PP405 is seen as a potential breakthrough for converting vellus hairs to terminal hairs, with users expressing both hope and skepticism. It is compared to treatments like minoxidil and finasteride, with discussions on side effects and marketing concerns.
The conversation is about a user switching to a more aggressive hair loss treatment, adding dutasteride 0.5mg and oral minoxidil 2.5mg to their current regimen of finasteride 0.02%, minoxidil 5%, biotin, massages, and microneedling. Users suggest increasing finasteride dosage and caution about potential side effects of oral minoxidil.
The conversation is about whether stemoxydine can shorten the dormant phase after a hair transplant, known as the ugly duckling phase. There is skepticism about whether it actually works as claimed.
The conversation discusses the use of dutasteride and finasteride for hair loss, including switching between them, optimal dosing, and managing side effects. The user has transcriptions of videos on these topics and offers them to others interested.
The post is an update on the user's hair loss journey. They have a strong hair follicle that has remained unaffected by hair loss for almost 3 years. The user is starting finasteride and using ketoconazole, alfatradiol, and oral castor oil for hair maintenance.
A user experienced significant hair shedding and thinning 10 months post-hair transplant despite using minoxidil and topical finasteride. They are considering switching to oral finasteride or dutasteride and are also dealing with scalp conditions like seborrheic dermatitis.
The user is using 5% topical minoxidil twice daily and 1.25 mg oral finasteride for hair thinning at the temples. They are considering switching to once-daily minoxidil due to scalp flakiness and future time constraints.
After five years of no progress with hair regrowth using oral finasteride and topical minoxidil, a person switched to a combination of topical dutasteride, minoxidil, tretinoin, ketoconazole, and hydrocortisone in November 2023 and finally saw results. They had previously experienced side effects like gynecomastia from finasteride.